BioFund Management Oy has sold all shares of Ark Therapeutics Group Plc, a biopharmaceutical company based in Finland and the UK. Bio Fund Ventures II LP invested in Ark in 2000 and Ark was listed on the London Stock Exchange main list in March 2004.
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater